AI and life sciences – unpacking FDA regulatory issues
A CLE WebinarWednesday, February 26, 2025
1 pm – 2 pm ET
12 pm – 1 pm CT
10 am – 11 am PT
Webinar login instructions will be sent upon completion of registration.
Following the presidential transition, FDA has been engaged in a flood of activity, with more on the horizon.
The intersection of artificial intelligence (AI) and life sciences is heavily influenced by FDA regulatory considerations, and further change is anticipated to continually impact biotech, biologics, life sciences, and medical device companies.
Please join Vernessa Pollard, Chair of DLA Piper’s FDA Regulatory practice, and Danny Tobey, Global Co-Chair and Chair of the firm’s Americas AI and Data Analytics practice, for a webinar to unpack the Administration’s regulatory changes and potential impacts to companies.
For more information
Please contact Ryan King with questions.
CLE:
DLA Piper LLP (US) has been certified by the State Bar of California, Illinois MCLE Board, the Board on Continuing Legal Education of the Supreme Court of New Jersey, and the New York State Continuing Legal Education Board as an Accredited Provider. The following CLE credit is being sought:
- California: 1.0 Credit (1.0 General, 0.0 Ethics)
- Illinois: 1.0 Credit (1.0 General, 0.0 Professional Responsibility)
- New Jersey: 1.2 Credits (1.2 General, 0.0 Ethics)
- New York: 1.0 Transitional & Non-Transitional Credit (1.0 Professional Practice, 0.0 Ethics)
CLE credit will be applied for in other states where DLA Piper has an office with the exception of Minnesota, North Carolina, and Puerto Rico.
Please click here to evaluate the program and request CLE credit. To comply with state CLE Board regulations, this process must be completed within 14 days of the program to receive credit.